Virology Outcomes of Tenofovir-lamivudine-dolutegravir in Treatment-naïve and Virologically Suppressed Individuals Switching From an NNRTI-based Regimen: An Observational Analysis at 13 Sites
TLD was well tolerated and achieved or maintained viral suppression (≤1000 copies/mL) in 90% of ART-naïve and 99% of participants with preswitch viral suppression. An emerging integrase strand transfer inhibitor mutation of uncertain significance was detected in only 1 participant. These data support early tolerability, virologic efficacy, and rare integrase strand transfer inhibitor resistance emergence with TLD transition or initiation in programmatic settings.
Authors
- Rodney Dawson (ORCID: https://orcid.org/0000-0001-9804-1588)
- Marije Van Schalkwyk (ORCID: https://orcid.org/0000-0003-2679-901X)
- Elizabeth Woolley
- Mina C. Hosseinipour (ORCID: https://orcid.org/0000-0003-2174-313X)
- Isaac Tsikhutsu
- Francis Kanyike
- Charles Flexner (ORCID: https://orcid.org/0000-0002-4495-5349)
- Deborah Langat (ORCID: https://orcid.org/0000-0003-0439-1099)
- Catherine Godfrey (ORCID: https://orcid.org/0000-0002-5797-7950)
- Viola Kirui
- Elliot Raizes (ORCID: https://orcid.org/0000-0001-5121-877X)
- Vuyokazi S Jezile
- Thando Mwelase
- Yvetot Joseph
- Mohammed Rassool (ORCID: https://orcid.org/0000-0003-0792-9050)
- Serena P. Koenig (ORCID: https://orcid.org/0000-0001-7464-275X)
- Lynne Cornelissen
- John W. Mellors (ORCID: https://orcid.org/0000-0002-3737-9742)
- Wadzanai Samaneka (ORCID: https://orcid.org/0000-0003-0215-9309)
- Yukari Carol Manabe (ORCID: https://orcid.org/0000-0001-8619-5598)
- Cornelius Munyanga
- Vanessa Rouzier (ORCID: https://orcid.org/0000-0002-9672-9474)
- Kelvin Mponda (ORCID: https://orcid.org/0000-0003-1030-1512)
- N. Sarita Shah
- Yeukai Musodza
- Cissy Kityo (ORCID: https://orcid.org/0000-0002-9286-7052)
- Penelope Madlala
- Damocles Patrice Severe
- Mulinda Nyirenda (ORCID: https://orcid.org/0000-0003-2037-7449)
- Abraham Siika (ORCID: https://orcid.org/0000-0001-7669-6612)
- Lerato Mohapi
- Suri Moonsamy
- Urvi M. Parikh (ORCID: https://orcid.org/0000-0002-4016-0629)
- Caitlyn McCarthy
- Carole L. Wallis (ORCID: https://orcid.org/0000-0001-8408-8772)
- Fatuma Some (ORCID: https://orcid.org/0000-0002-7127-3909)
- Rosie Mngqibisa (ORCID: https://orcid.org/0000-0002-6540-5733)
- Lindee Ganger
- Nadia Magengo
- Daphie Jean François
- Noluthando Mwelase
- Jean Bernard Marc (ORCID: https://orcid.org/0009-0008-1428-5015)
- Michael Hughes (ORCID: https://orcid.org/0000-0002-8109-8702)
- Marie Jude Jean Louis
- Petronella Casey
Institutions
- Technology Service Corporation (United States) (US)
- Harvard University (US)
- Johns Hopkins University (US)
- Moi University (KE)
- Emory University (US)
- University of Cape Town (ZA)
- University of Pittsburgh (US)
- University of the Witwatersrand (ZA)
- Stellenbosch University (ZA)
- Johns Hopkins Medicine (US)
- Kenya Medical Research Institute (KE)
- Lung Institute (US)
- Cancer Research And Biostatistics (US)
- Innovative Clinical Research (US)
- Blantyre Institute for Community Ophthalmology (MW)
- Christian Health Association of Malawi (MW)
- United Therapeutics (United States) (US)
- Gheskio Centers (HT)
- National Labor College (US)
- Perinatal HIV Research Unit (ZA)
- Helen Joseph Hospital (ZA)
- Joint Clinical Research Centre (UG)
- Walter Reed Army Institute of Research (US)
Publication Details
- Journal
- Open Forum Infectious Diseases
- Published
- 2025-05-02
- DOI
- https://doi.org/10.1093/ofid/ofaf270
- Citations
- 1
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.40
Funders
- U.S. Department of Defense
- U.S. Department of Health and Human Services
- U.S. Department of State
- United States Agency for International Development
- ACT Government
- National Institutes of Health
- Centers for Disease Control and Prevention
- National Institute of Allergy and Infectious Diseases